Patients with non–small cell lung cancer (NSCLC), carrying a MET splicing variant resulting in exon 14 skipping (METex14 skipping) mutations and impaired receptor breakdown, are responsive to small molecule inhibitors of MET (7). The gene discussed is MET; the disease is non-small cell lung carcinoma.